Tokyo, Japan, July 5, 2021 – MilliporeSigma today commemorated the fifth anniversary of its M Lab™ Collaboration Center in Tokyo, a simulated non-GMP lab to support pharmaceutical and biopharmaceutical customers in Japan on their process development needs. The facility is equipped and designed to recreate a manufacturing environment, allowing customers to operate real equipment, evaluate processes and conduct training across the entire process, from upstream to downstream and through final fill.
“Over the past five years, the Tokyo M Lab™ Collaboration Center has supported our Japanese customers by providing customizable, full end-to-end solutions in process development, from early stage to industrial production,” said Isao Hatano, Head of Process Solutions, Japan, at MilliporeSigma. “It was imperative that we continue to provide these services during the pandemic to help ensure life-saving therapies get to the patients who need them most.”
As a result of the Covid-19 pandemic, travel restrictions and workplace capacity were activated, and on-site visits were paused. MilliporeSigma quickly implemented new ways to partner with customers in conducting online lab tours, troubleshooting and training activities, as well as performing virtual or 3D demonstrations and experiments.
Since its opening in 2016, the site has held more than 400 customer activities, including MILLI-SCHOOL™ technical education events and hands-on knowledge transfer experiments in the lab, which have helped drug developers solve their toughest problems. Additionally, the M Lab™ Collaboration Center has played an active role in bringing the company’s global SPARK™ volunteer program to local students to spark curiosity in the next generation of scientists and expose them to careers in Science, Technology, Engineering, and Math (STEM). The SPARK™ program in Japan features hands-on interactive science lessons, lab tours, and engagement sessions with scientists.
MilliporeSigma’s M Lab™ Collaboration Center in Tokyo is among the company’s nine centers worldwide, located in large biotech communities around the world, offering customers opportunities for collaboration, technical guidance, and education provided by MilliporeSigma scientists and engineers.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 22,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany generated sales of €16.2 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.